MedTrace Logo

Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes

NCT03085771 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-05-26

No results posted yet for this study

Summary

The general aim of this study is to investigate the influence of systemic administration of Desferal (Deferoxamine \[DFO\]) on the response to hypoxic challenge in patients with diabetes mellitus (DM).

The investigation will elucidate if DFO can restore:

* the impaired angiogenetic response to hypoxia in patients with type 1 DM.
* the disturbed respiratory and cardiovascular regulation in response to hypoxia in patients with DM type 1

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

desferal

It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.

DRUG

Isotonic saline

It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.

Sponsors & Collaborators

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Sergiu Catrina, Ass. prof. · Karolinska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2023-12-12
Completion
2024-12-12

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03085771 on ClinicalTrials.gov